A Five-Day Gradual Reduction Regimen of Chlormadinone Reduces Premenstrual Anxiety and Depression: A Pilot Study

Archives of Medical Research

Volumn 37, Issue 7, 2006, Pages 907-913

  Contreras, Carlos M ^a   Azamar Arizmendi, Georgina ^a,b   Saavedra, Margarita ^a   Hernández Lozano, Minerva ^a  

^a Instituto de Investigaciones Biomédicas   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Anxiety; Chlormadinone; Depression; Premenstrual dysphoric disorder; Premenstrual syndrome; Progesterone

Indexed keywords

CHLORMADINONE; PLACEBO;

ANXIETY DISORDER; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HOPELESSNESS; HORMONAL THERAPY; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MENTAL CONCENTRATION; MENTAL INSTABILITY; MUSCLE CRAMP; PILOT STUDY; PREMENSTRUAL DYSPHORIC DISORDER; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SWELLING; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; ANXIETY; CHLORMADINONE ACETATE; DEPRESSION; FEMALE; HUMANS; PILOT PROJECTS; PLACEBOS; PREMENSTRUAL SYNDROME; TREATMENT OUTCOME;

EID: 33748458445     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.05.001     Document Type: Article

References (52)

1. Cronje W.H., and Studd J.W. Premenstrual syndrome and premenstrual dysphoric disorder. Primary Care. Clinic in Office Practice 29 (2002) 1-12
2. Maskall D., Lam R., Misri S., Carter D., Kuan A., Yatham L., et al. Seasonality of symptoms in women with late luteal phase dysphoric disorder. Am J Psychiat 154 (1997) 1436-1441
3. Ramcharan S., Love E.J., Fick G.H., and Golfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 45 (1992) 377-392
4. Pearlstein T. Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy?. Am J Obstet Gynecol 173 (1995) 646-653
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed (2000), American Psychiatric Association, Washington pp. 771-775
6. Deuster P., Adera T., and South-Paul J. Biological, social and behavioral factors associated with premenstrual syndrome. Arch Fam Med 8 (1999) 122-128
7. Moline M., and Zendell S. Evaluating and managing premenstrual syndrome. Medscape Women's Health 5 (2000) 1
8. Mortola J.F., Girton L., Beck L., and Yen S.S. Diagnosis of premenstrual syndrome by a simple prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 76 (1990) 302-307
9. Freeman E.W., De Rubeis R.J., and Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiat Res 65 (1996) 97-106
10. Halbreich U. Hormonal interventions with psychopharmacological potential: an overview. Psychopharmacol Bull 33 (1997) 281-286
11. Freeman E.W., and Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiat 156 (1999) 1403-1408
12. Johnson S. Premenstrual syndrome therapy. Clin Obstet Gynecol 41 (1998) 405-421
13. Freeman E., Rickels K., Sondheimer S.J., and Polansky M.A. Double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274 (1995) 51-57
14. Yonkers K., Halbreich U., Freeman E., Brown C., Endicott J., Frank E., et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA 278 (1997) 983-988
15. Freeman E.W., Rickels K., Sondheimer S.J., and Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. Arch Gen Psychiat 56 (1999) 932-939
16. Tiemstra J., and Patel K. Hormonal therapy in the management of premenstrual syndrome. J Am Board Fam Pract 11 (1998) 378-381
17. Warren M., Biller B., and Shangold M. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 180 (1999) 42-48
18. Fitzpatrick L., and Good A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 72 (1999) 389-397
19. Mortola J.F., Girton L., and Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 72 (1991) 252A-252F
20. Mortola J.F. Premenstrual syndrome: pathophysiologic considerations. N Engl J Med 338 (1998) 256-257
21. Van Leusden H.A. Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency. Lancet 346 (1995) 1443-1444
22. Soderpalm A.H., Lindsey S., Purdy R.H., Hauger R., and Wit de H. Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 29 (2004) 339-354
23. Reddy D.S., and Apanites L.A. Anesthetic effects of progesterone are undiminished in progesterone receptor knockout mice. Brain Res 1033 (2005) 96-101
24. Smith A.F., and Pittaway A.J. Premedication for anxiety in adult day surgery. Cochrane Database Syst Rev 3 (2000) CD002192
25. Reddy D.S. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 62 (2004) 99-118
26. Martínez-Mota L., Contreras C., and Saavedra M. Progesterone reduces immobility in rats forced to swim. Arch Med Res 30 (1999) 286-289
27. Frye C.A., and Walf A.A. Hippocampal 3alpha, 5alpha-THP may alter depressive behavior of pregnant and lactating rats. Pharmacol Biochem Behav 78 (2004) 531-540
28. Smith S.S. Withdrawal properties of a neuroactive steroid: implications for GABA(A) receptor gene regulation in the brain and anxiety behavior. Steroids 67 (2002) 519-528
29. Kendler K., Karkowski L., Corey L., and Neale M. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiat 155 (1998) 1234-1240
30. Shippen E. Progesterone organogel for premenstrual dysphoric disorder. J Am Acad Child Adolesc Psychiat 40 (2001) 262-264
31. Dennerstein L., Spencer-Garner C., Gotts G., Brown J.B., Smith M.A., and Burrows G.D. Progesterone and premenstrual syndrome: a double blind crossover trial. Br Med J 290 (1985) 1617-1621
32. West C.P. Inhibition of ovulation with oral progestins effectiveness in premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 34 (1990) 119-128
33. Wyatt K., Dimmock P., Jones P., Obhrai M., and O'Brien S. Efficacy of progesterone and progestagens in management of premenstrual syndrome: systematic review. Br Med J 323 (2001) 1-8
34. Baker E.R., Best R.G., Manfredi R.L., Demers L.M., and Wolf G.C. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. J Assist Reprod Genet 2 (1995) 205-209
35. Epperson C.N., Wisner K.L., and Yamamoto B. Gonadal steroids in treatment of mood disorders. Psychosomatic Med 61 (1999) 676-697
36. Pearlstein T., Stone A., Lund S., Scheft H., Zlotnick C., and Brown W. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17 (1997) 261-266
37. Sampson G.A., Heathcote P.R., Wordsworth J., Presscott P., and Hodgson A. Premenstrual syndrome. A double-blind cross-over study of treatment with the dydroprogesterone and placebo. Br J Psychiat 153 (1988) 232-235
38. Wang M., Seippel L., Purdy R., and Backstrom T. Relationship between symptom severity and steroid variation in woman with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metabol 81 (1996) 1076-1082
39. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., and Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90 (1997) 709-714
40. Sundberg D.K. Postsynaptic receptors. In: Conn M. (Ed). Neuroscience in Medicine (1995), Lippincott, Philadelphia 115-133
41. A receptor. Mechanism of action and physiological significance. Prog Neurobiol 38 (1992) 379-395
42. A receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal. J Neurosci 23 (2003) 11711-11724
43. Mhatre M.C., McKenzie S.E., and Gonzalez L.P. Diazepam during prior ethanol withdrawals does not alter seizure susceptibility during a subsequent withdrawal. Pharmacol Biochem Behav 68 (2001) 339-346
44. Contreras C.M., Molina M., Saavedra M., and Martínez Mota L. Lateral septal neuronal firing increases during proestrus-estrus in the rat. Physiol Behav 68 (2000) 279-284
45. Freeman M.E. The neuroendocrine control of the ovarian cycle of the rat. In: Knobil E., and Neill J.D. (Eds). The Physiology of Reproduction. 2nd ed (1994), Raven Press, New York 613-621
46. Contreras C.M., Martínez-Mota L., Saavedra M., and Molina M. Desipramine restricts estral cycle oscillations in swimming. Prog NeuroPsychopharmacol Biol Psychiat 22 (1998) 1121-1128
47. Fernández-Guasti A., Martínez-Mota L., Estrada-Camarena E., Contreras C.M., and López Rubalcava C. Chronic treatment with desimipramine induces an estrous cycle-dependent anxiolytic-like action in the burying behavior, but not in the elevated plus-maze test. Pharmacol Biochem Behav 63 (1999) 13-20
48. Martínez-Mota L., Estrada Camarena E., López Ruvalcaba C., Contreras C.M., and Fernández-Guasti A. Interaction of desipramine with steroid hormones on experimental anxiety. Psychoneuroendocrinology 25 (2000) 109-120
49. Molina-Hernández M., Contreras C.M., and Téllez Alcántara P. Diazepam increases the number of punished responses in a conflict-operant paradigm during late proestrus and estrus in the Wistar rat. Neuropsychobiology 43 (2001) 29-33
50. McGrath A., Crome P., and Crome I.B. Substance misuse in the older population. Postgrad Med J 81 (2005) 228-231
51. Lingford-Hughes A.R., Davies S.J.C., McIver S., Williams T.M., Daglish M.R.C., and Nutt D.J. Addiction: imaging in clinical neuroscience. Br Med Bull 65 (2003) 209-222
52. Kreek M.J., Bart G., Lilly C., Laforge K.S., and Nielsen D.A. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57 (2005) 1-26